Mankind Pharma Q2 profit rises 38% to ₹712 crore as revenue grows 17%

Mankind Pharma reported strong second-quarter FY27 results, with revenue rising about 17% year over year to ₹4,338 crore and profit increasing roughly 38–39% to ₹712–716 crore. EBITDA grew about 27%, while its margin expanded 210 basis points to around 27%. Domestic pharmaceutical sales excluding consumer healthcare grew 15.9%, led by chronic and acute therapies, and international business increased about 33%; consumer healthcare growth was muted. For the first half of FY27, revenue reached ₹8,368 crore, up 15%, and the company highlighted its acquisition of Armed Cell Therapeutics as a step into next-generation CAR-T therapies. Mankind shares rose 4.5% following the results.